"Improving access to our authentic FDA-approved treatments is central to our mission at Novo Nordisk," said Novo Nordisk's executive vice president Dave Moore in a statement.

“At the ESC congress, we are presenting new data substantiating the unique range of benefits semaglutide has on people with heart and kidney disease, as demonstrated in both clinical trials and in the...